Shots:
- Esperion to receive $30M up front, ~$175M as sales milestones along with royalties from 5-20% on sales in the territory. Daiichi Sankyo will get exclusive commercialization rights to bempedoic acid and bempedoic acid/ezetimibe combination tablet in S. Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia, and Myanmar
- The agreement allows for the expansion across geographies in Asia, the Middle East and Latin America. While Daiichi Sankyo holds commercialization rights in these territories, the rights for development and regulatory activities will remain with Esperion
- With this deal, combined milestones from the Daiichi Sankyo now total over $1.1B
Click here to read full press release/ article | Ref: Globe Newswire | Image: BioSpace
The post Daiichi Sankyo Expands its Collaboration with Esperion to Additional Territories first appeared on PharmaShots.
